Literature DB >> 26873702

[Development of serous retinopathy during therapy of a metastatic cutaneous melanoma].

I Lüdeke1, P Terheyden2, S Grisanti3, M Lüke3.   

Abstract

Inhibitors of the mitogen-activated protein kinase (MAPK) signal pathway have decisively improved the prognosis of metastatic cutaneous melanoma in patients with an activating mutation in position V600 of the BRAF gene. We report on a patient who was regularly examined in our clinic while participating in a randomized blinded clinical trial. The aim of this trial was to examine the effectiveness and tolerability of a combination of the BRAF inhibitor dabrafenib and the MAPK kinase (MEK) inhibitor trametinib compared with a monotherapy with dabrafenib (plus placebo). During therapy the patient developed a diffuse neuroretinal detachment which could not be completely reversed after discontinuation of the study medication.

Entities:  

Keywords:  BRAF inhibitor; Chorioretinopathy; Dabrafenib; MEK inhibitor; Trametinib

Mesh：

Substances：

Year:  2016        PMID： 26873702     DOI： 10.1007/s00347-016-0226-8

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  8 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

Review 2.  Understanding, recognizing, and managing toxicities of targeted anticancer therapies.

Authors:  Grace K Dy; Alex A Adjei
Journal:  CA Cancer J Clin       Date:  2013-05-28       Impact factor: 508.702

3.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman
Journal:  Lancet       Date:  2012-06-25       Impact factor: 79.321

4.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

Authors:  Grant A McArthur; Paul B Chapman; Caroline Robert; James Larkin; John B Haanen; Reinhard Dummer; Antoni Ribas; David Hogg; Omid Hamid; Paolo A Ascierto; Claus Garbe; Alessandro Testori; Michele Maio; Paul Lorigan; Celeste Lebbé; Thomas Jouary; Dirk Schadendorf; Stephen J O'Day; John M Kirkwood; Alexander M Eggermont; Brigitte Dréno; Jeffrey A Sosman; Keith T Flaherty; Ming Yin; Ivor Caro; Suzanne Cheng; Kerstin Trunzer; Axel Hauschild
Journal:  Lancet Oncol       Date:  2014-02-07       Impact factor: 41.316

5.  Transient MEK inhibitor-associated retinopathy in metastatic melanoma.

Authors:  U Urner-Bloch; M Urner; P Stieger; N Galliker; N Winterton; A Zubel; L Moutouh-de Parseval; R Dummer; S M Goldinger
Journal:  Ann Oncol       Date:  2014-05-26       Impact factor: 32.976

6.  Docosahexaenoic acid prevents apoptosis of retina photoreceptors by activating the ERK/MAPK pathway.

Authors:  Olga Lorena German; María Fernanda Insua; Claudia Gentili; Nora P Rotstein; Luis E Politi
Journal:  J Neurochem       Date:  2006-09       Impact factor: 5.372

7.  Involvement of MAPKs in endostatin-mediated regulation of blood-retinal barrier function.

Authors:  Matthew Campbell; Ross Collery; Alice McEvoy; Tom A Gardiner; Alan W Stitt; Brenda Brankin
Journal:  Curr Eye Res       Date:  2006-12       Impact factor: 2.424

8.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962
  8 in total
  1 in total

1.  [Paraneoplastic serous retinopathies: hormones, mediators, and inhibitors].

Authors:  R S Grajewski; L M Heindl
Journal:  Ophthalmologe       Date:  2017-04       Impact factor: 1.059
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.